background
respiratori
syncyti
viru
rsv
infect
lung
transplant
recipi
ltr
associ
signific
morbid
mortal
immunoglobulin
ribavirin
palivizumab
suggest
treatment
preemptiv
therapeut
purpos
howev
absenc
random
placebocontrol
trial
efficaci
controversi
toxic
well
cost
concern
method
retrospect
review
case
lower
respiratori
tract
rsv
infect
adult
ltr
diagnosi
base
clinic
histori
combin
posit
polymeras
chain
reaction
pcr
andor
viral
cultur
bronchoalveolar
lavag
bal
specimen
result
ten
symptomat
patient
identifi
men
women
age
rang
year
hospit
communityacquir
respiratori
tract
infect
two
patient
concomit
acut
grade
graft
reject
patient
concomit
bacteri
pneumonia
eight
patient
receiv
specif
antirsv
treatment
clinic
stabil
andor
improv
time
rsv
diagnosi
patient
grade
allograft
reject
requir
mechan
ventil
receiv
ribavirin
palivizumab
patient
recov
without
complic
persist
rsv
infect
howev
bronchiol
obliteran
bo
stage
worsen
patient
mean
followup
month
conclus
data
suggest
mild
rsv
infect
ltr
might
evolv
favor
absenc
specif
antivir
therapi
howev
observ
need
confirm
larg
clinic
trial
specif
investig
develop
bo
untreat
vs
treat
patient
placebocontrol
trial
clearli
establish
indic
efficaci
popul
moreov
widespread
use
limit
concern
toxic
mainli
nephrotox
elev
cost
recommend
often
controversi
establish
primarili
bone
marrow
transplant
bmt
recipi
littl
publish
treatment
rsv
infect
solidorgan
transplant
recipi
offici
recommend
specif
manag
rsv
transplant
patient
avail
countri
unit
state
sweden
switzerland
switzerland
preemptiv
therapi
case
lowgrad
immunosuppress
prophylaxi
sever
immunosuppress
combin
treatment
immunoglobulin
ig
ribavirin
palivizumab
case
proven
infect
suggest
bmt
recipi
ltr
get
better
overview
clinic
evolut
rsv
infect
ltr
retrospect
search
virolog
report
identifi
adult
ltr
proven
lower
respiratori
tract
rsv
infect
herein
describ
clinic
evolut
accord
treatment
studi
conduct
universitair
de
hug
centr
hospitali
universitair
vaudoi
chuv
switzerland
hospit
belong
centr
universitair
romand
de
transplant
perform
ltr
sinc
hospit
use
similar
immunosuppress
regimen
initi
induct
longterm
tripl
associ
includ
either
cyclosporin
trough
target
level
gliter
tacrolimu
trough
target
level
gliter
everolimu
trough
target
level
gliter
mycophenol
mofetil
gday
lowdos
prednison
mgday
sinc
ltr
follow
prospect
cohort
studi
n
identifi
case
lower
respiratori
tract
infect
due
rsv
ltr
ltr
cohort
wit
total
viral
respiratori
tract
infect
novemb
march
includ
episod
respiratori
secret
posit
rsv
patient
men
women
age
rang
year
thu
rsv
account
viral
respiratori
infect
diagnosi
rsv
establish
viral
cultur
patient
pcr
case
techniqu
patient
concomit
viral
pathogen
found
addit
ltr
rsv
detect
pcr
annual
control
absenc
respiratori
symptom
patient
exclud
analysi
none
patient
secondari
respiratori
specimen
posit
rsv
later
time
period
clinic
characterist
case
present
detail
tabl
patient
symptomat
communityacquir
respiratori
tract
infect
time
posit
respiratori
tract
specimen
episod
occur
winter
earli
spring
without
epidemiolog
intercas
link
seven
episod
occur
least
year
transplant
occur
month
occur
day
rang
day
posttransplant
three
patient
concomit
biopsyproven
allograft
reject
patient
acut
grade
reject
treat
antithymocyt
globulin
intraven
methylprednisolon
respect
patient
acut
grade
reject
requir
specif
antireject
therapi
two
patient
concomit
infect
requir
specif
therapi
patient
bacteri
pneumonia
patient
symptomat
cytomegaloviru
cmv
diseas
patient
treat
asymptomat
concomit
lowgrad
reactiv
cmv
replic
new
infiltr
chest
xray
note
patient
patient
individu
evolut
data
forc
expiratori
volum
second
fev
shown
tabl
compar
month
prior
rsv
infect
fev
chang
rang
patient
fev
reduct
patient
four
patient
never
recov
prersv
infect
fev
valu
patient
patient
patient
patient
patient
recov
rsv
infect
eight
patient
alreadi
clinic
improv
time
rsv
diagnosi
patient
immunosuppress
temporarili
reduc
howev
patient
given
specif
rsv
treatment
strikingli
group
includ
patient
concomitantli
receiv
methyprednisolon
reject
episod
fev
reduct
patient
also
transient
fev
reduct
two
patient
treat
ribavirin
day
oral
mgday
intraven
mgkg
time
daili
concomit
intraven
palivizumab
singl
dose
mgkg
tabl
includ
patient
requir
antithymocyt
globulin
nonrespond
con
detect
rsv
pcr
respiratori
secret
highli
sensit
specif
current
consid
best
avail
test
diagnosi
respiratori
tract
infect
adult
lung
transplant
recipi
implement
mani
lung
transplant
center
may
increas
number
patient
diagnos
rsv
infect
therefor
guidelin
need
help
clinician
decid
whether
ltr
document
rsv
requir
specif
treatment
herein
report
case
proven
communityacquir
lower
respiratori
tract
rsv
infect
adult
lung
transplant
recipi
surprisingli
result
delay
diagnosi
alreadi
improv
clinic
diagnosi
rsv
infect
made
patient
therefor
recov
without
receiv
specif
antirsv
therapi
case
immunosuppress
temporarili
reduc
patient
new
groundglass
opac
comput
tomographi
scan
caus
rsv
found
clear
spontan
previous
describ
bmt
recipi
rsv
also
recov
lung
asymptomat
lung
transplant
recipi
inde
eleventh
asymptomat
patient
includ
case
descript
posit
rsv
pcr
annual
control
bal
assess
remain
clinic
stabl
without
treatment
case
illustr
possibl
detect
bia
studi
clearli
patient
asymptomat
rsv
infect
would
seek
medic
advic
true
incid
respiratori
tract
infect
due
rsv
ltr
could
higher
observ
high
number
rsvinfect
ltr
spontan
evolv
favor
contrast
previou
report
support
earli
specif
antirsv
therapi
especi
aerosol
ribavirin
rais
critic
question
regard
aggress
therapeut
approach
recommend
accord
review
previous
publish
case
rsv
infect
among
adult
ltr
patient
less
immunosuppress
describ
elsewher
tabl
previou
studi
suggest
sever
rsv
infect
may
occur
earli
transplant
immun
respons
compromis
howev
recent
studi
report
infect
first
month
posttransplant
cohort
patient
develop
rsv
infect
first
month
posttransplant
evolv
favor
without
specif
therapi
clearli
studi
need
determin
whether
time
transplant
impact
sever
diseas
necess
treatment
rsv
infect
acut
reject
episod
suggest
risk
factor
develop
bo
also
suggest
rsv
infect
may
trigger
acut
reject
strikingli
observ
postrsv
infect
worsen
bo
stage
patient
mean
followup
time
month
interestingli
half
patient
also
experienc
postrsv
acut
reject
episod
small
number
case
confound
reject
episod
remain
difficult
ascertain
potenti
respons
rsv
infect
develop
andor
worsen
bo
cohort
howev
warrant
investig
larg
ltr
cohort
possibl
causal
mild
rsv
infect
per
se
evolv
favor
without
specif
treatment
bo
would
potenti
major
diagnost
therapeut
implic
inde
associ
would
support
screen
rsv
ltr
even
mild
symptom
moreov
one
would
establish
control
trial
whether
specif
antirsv
treatment
could
prevent
bo
worsen
condit
one
forget
increas
cost
potenti
advers
effect
associ
specif
rsv
therapi
immunoglobulin
ribavirin
pavilizumab
may
signific
advers
effect
studi
incid
seriou
advers
effect
ribavirin
high
hemolyt
anemia
occur
treat
patient
studi
none
patient
treat
ribavirin
develop
seriou
advers
effect
likewis
pelaez
et
al
report
episod
mild
revers
anemia
among
ltr
treat
oral
ribavirin
rsv
suggest
oral
ribavirin
might
efficientbut
less
expensivethan
nebul
ribavirin
costeffect
analys
pavilizumab
treatment
rsv
infect
adult
miss
studi
present
avail
prophylaxi
infant
requir
much
smaller
dose
adult
conclus
observ
support
ltr
without
sever
diseas
due
rsv
without
particularli
enhanc
immunosuppress
eg
antithymocyt
globulin
necessarili
requir
specif
antivir
treatment
contrast
previou
report
expert
opinion
favor
earli
specif
antirsv
treatment
ltr
howev
earlier
studi
retrospect
includ
small
number
patient
assess
sever
differ
respiratori
virus
contain
incomplet
clinic
inform
final
mani
recommend
deriv
bmt
recipi
repres
clinic
distinct
patient
popul
therefor
suggest
ltr
posit
rsv
least
month
transplant
minor
clinic
symptom
may
observ
care
transient
reduct
immunosuppress
specif
antirsv
treatment
initi
case
clinic
deterior
howev
random
clinic
trial
warrant
determin
whether
less
aggress
stepbystep
approach
safe
expos
ltr
increas
risk
bo
develop
thank
team
laboratori
virolog
lung
transplant
program
geneva
univers
hospit
vaud
univers
hospit
help
clinic
manag
case
none
author
conflict
interest
disclos
